You are here

ACCURATE NONINVASIVE TEST OF STEATORRHEA IN INFANTS

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 2R44DK056561-02
Agency Tracking Number: DK056561
Amount: $0.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: N/A
Solicitation Number: N/A
Timeline
Solicitation Year: N/A
Award Year: 2002
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
BIOCHEMANALYSIS CORPORATION 2201 W CAMPBELL PARK DR
CHICAGO, IL 60612
United States
DUNS: N/A
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 MORTEZA JANGHORBANI
 (312) 243-5988
 MJANGHOR@UIC.EDU
Business Contact
 DOROTHY CRIBBS
Phone: (312) 243-5988
Email: DCRIBBS@FULLNET.COM
Research Institution
N/A
Abstract

DESCRIPTION (provided by the applicant): The long-term objectives of this
proposed project are to develop a "Test Kit" for quantitative assessment of
steatorrhea in infants without the need for control of dietary fat intake and
quantitative collections of stools for several days as is the case with the
current "Gold Standard," viz, the 72-hour fecal fat method. Our proposed "Test
Kit" is based on administering a feeding of infant formula containing a
suitably labeled 13C-triglyceride (TG), a trace amount of the nonabsorbable
marker dysprosium chloride (DyC1-3) and the visual marker Brilliant Blue
followed by laboratory analysis of Dy and 13C-Excess in one or more sample(s)
of stool containing the visual marker. The research conducted during Phase-I of
this grant has led to the selection of 1,3-(13C-2) dipalmitoyl, 2-lauryl
glycerol (P*LP*) as the most suitable TG* for applications in infants. During
Phase II of the project, we propose to conduct clinical protocols with cystic
fibrosis and healthy infants in order to: (1) define the parameters of the
expected linear correlation between fecal excretion of P*LP* and fecal fat, (2)
demonstrate the significance of this novel method in medical management of
infants with steatorrhea, and (3) obtain research data necessary for the
manufacture of a safe and noninvasive "Test Kit" for accurate assessment of
steatorrhea in infants. The "Test Kit" has widespread applications in clinical
management of infants with a wide range of disorders leading to steatorrhea.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government